{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:22:56Z","timestamp":1790652176830,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Approximately 20% of intensive care unit (ICU) patients have cancer, and their prognosis has markedly improved in recent years. In addition to improved treatment in the ICU, this is a result of advancements in cancer therapies, including the use of targeted therapies (TTs), such as antibodies and small-molecule kinase inhibitors. Despite the increasing use of TT, there are currently no comprehensive studies examining critically ill cancer patients receiving TT in the ICU. We studied the clinical characteristics of a multicenter cohort of cancer patients who received TT in the ICU. To this end, we extracted data from the iCHOP Registry, comprising critically ill cancer patients from nine centers in Germany and Austria, and analyzed patient characteristics, cancer therapies, and survival outcomes. We then employed Cox proportional hazards regression and Kaplan\u2012Meier survival analyses to explore factors associated with mortality. Of the 1,762 cancer patients admitted to the ICU who were analyzed for this study, 106 patients (6%) received TT in the ICU, such as antibody-based treatments, kinase inhibitors and proteasome inhibitors. Although the TT recipients were younger, there were several pronounced high-risk features in the TT cohort, as indicated by a greater proportion of hematologic malignancies and autologous stem cell transplantation (SCT), a greater percentage of progressive disease and fewer patients in complete remission at ICU admission than in patients not receiving TT in the ICU. Despite these more pronounced risk features, TT patients had a slightly longer median OS than did the other patients according to Kaplan\u2012Meier analysis. The factors associated with mortality according to Cox proportional hazards regression analysis included advanced directives, disease progression, SOFA score, invasive mechanical ventilation (IMV), renal replacement therapy, and duration of ICU and hospital stay. Critically ill cancer patients receiving TT in the ICU had distinct characteristics but had comparable survival outcomes compared to patients receiving any other or no antineoplastic therapy in the ICU. While disease status at ICU admission remains crucial, the present study indicates the feasibility and potential benefits of TT in selected ICU patients.<\/jats:p>","DOI":"10.1007\/s00277-025-06400-3","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:31:59Z","timestamp":1746851519000},"page":"2937-2946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeted antineoplastic therapy in critically ill cancer patients: a multicenter analysis of the iCHOP registry"],"prefix":"10.1007","volume":"104","author":[{"given":"Anthea","family":"Storck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kochanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schellongowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Staudinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Buchtele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Cserna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Brueder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherina","family":"Lueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Liebregts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asterios","family":"Tzalavras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Hammersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kroschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randolf","family":"Forkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Kiehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Grans-Sibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Garcia","family":"Borrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Hendrik","family":"Naendrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Shimabukuro-Vornhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Eichenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"B\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Intensive Care in Hematologic and Oncologic Patients (iCHOP) working group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"issue":"4","key":"6400_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00063-019-0594-3","volume":"115","author":"M Kochanek","year":"2020","unstructured":"Kochanek M, Shimabukuro-Vornhagen A, Russ K, Beutel G, Lueck C, Kiehl M et al (2020) [Prevalence of cancer patients in German intensive care units]. Med Klin Intensivmed Notfmed 115(4):312\u2013319","journal-title":"Med Klin Intensivmed Notfmed"},{"issue":"27","key":"6400_CR2","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1200\/JCO.2016.66.9549","volume":"34","author":"M Soares","year":"2016","unstructured":"Soares M, Bozza FA, Azevedo LC, Silva UV, Correa TD, Colombari F et al (2016) Effects of organizational characteristics on outcomes and resource use in patients with Cancer admitted to intensive care units. J Clin Oncol 34(27):3315\u20133324","journal-title":"J Clin Oncol"},{"issue":"9","key":"6400_CR3","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1007\/s00134-017-4884-z","volume":"43","author":"E Azoulay","year":"2017","unstructured":"Azoulay E, Schellongowski P, Darmon M, Bauer PR, Benoit D, Depuydt P et al (2017) The intensive care medicine research agenda on critically ill oncology and hematology patients. Intensive Care Med 43(9):1366\u20131382","journal-title":"Intensive Care Med"},{"issue":"6","key":"6400_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3322\/caac.21351","volume":"66","author":"A Shimabukuro-Vornhagen","year":"2016","unstructured":"Shimabukuro-Vornhagen A, Boll B, Kochanek M, Azoulay E, von Bergwelt-Baildon MS (2016) Critical care of patients with cancer. CA Cancer J Clin 66(6):496\u2013517","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6400_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/caac.21702","volume":"72","author":"A Shimabukuro-Vornhagen","year":"2022","unstructured":"Shimabukuro-Vornhagen A, Boll B, Schellongowski P, Valade S, Metaxa V, Azoulay E et al (2022) Critical care management of chimeric antigen receptor T-cell therapy recipients. CA Cancer J Clin 72(1):78\u201393","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6400_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T et al (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 6(1):201","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"6400_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP et al (2022) Polatuzumab Vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med 386(4):351\u2013363","journal-title":"N Engl J Med"},{"issue":"26","key":"6400_CR8","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1056\/NEJMc1714337","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Seymour JF, Hiddemann W (2017) Obinutuzumab treatment of follicular lymphoma. N Engl J Med 377(26):2605\u20132606","journal-title":"N Engl J Med"},{"issue":"10450","key":"6400_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","volume":"404","author":"P Borchmann","year":"2024","unstructured":"Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M et al (2024) Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet 404(10450):341\u2013352","journal-title":"Lancet"},{"issue":"4","key":"6400_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M et al (2024) Daratumumab, bortezomib, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 390(4):301\u2013313","journal-title":"N Engl J Med"},{"issue":"10","key":"6400_CR11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP et al (2017) Long-Term outcomes of Imatinib treatment for chronic myeloid leukemia. N Engl J Med 376(10):917\u2013927","journal-title":"N Engl J Med"},{"issue":"25","key":"6400_CR12","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMra2113347","volume":"386","author":"R Foa","year":"2022","unstructured":"Foa R, Chiaretti S (2022) Philadelphia Chromosome-Positive acute lymphoblastic leukemia. N Engl J Med 386(25):2399\u20132411","journal-title":"N Engl J Med"},{"issue":"22","key":"6400_CR13","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F et al (2018) Pembrolizumab plus chemotherapy in metastatic Non-Small-Cell lung Cancer. N Engl J Med 378(22):2078\u20132092","journal-title":"N Engl J Med"},{"issue":"23","key":"6400_CR14","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-Line Atezolizumab plus chemotherapy in Extensive-Stage Small-Cell lung Cancer. N Engl J Med 379(23):2220\u20132229","journal-title":"N Engl J Med"},{"issue":"14","key":"6400_CR15","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1002\/cncr.31409","volume":"124","author":"SM Pastores","year":"2018","unstructured":"Pastores SM, Goldman DA, Shaz DJ, Kostelecky N, Daley RJ, Peterson TJ et al (2018) Characteristics and outcomes of patients with hematologic malignancies receiving chemotherapy in the intensive care unit. Cancer 124(14):3025\u20133036","journal-title":"Cancer"},{"issue":"10","key":"6400_CR16","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00277-014-2141-x","volume":"93","author":"P Wohlfarth","year":"2014","unstructured":"Wohlfarth P, Staudinger T, Sperr WR, Bojic A, Robak O, Hermann A et al (2014) Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit. Ann Hematol 93(10):1629\u20131636","journal-title":"Ann Hematol"},{"issue":"7","key":"6400_CR17","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1007\/s00134-019-05650-w","volume":"45","author":"S Assoun","year":"2019","unstructured":"Assoun S, Lemiale V, Azoulay E (2019) Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. Intensive Care Med 45(7):988\u2013997","journal-title":"Intensive Care Med"},{"issue":"6","key":"6400_CR18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1177\/0885066618787788","volume":"34","author":"A Pistone","year":"2019","unstructured":"Pistone A, Durieux V, Grigoriu B, Meert AP (2019) Management of acute complications of targeted therapy in patients with cancer: A review of cases managed in ICU. J Intensive Care Med 34(6):435\u2013448","journal-title":"J Intensive Care Med"},{"issue":"12","key":"6400_CR19","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and Meta-analysis. JAMA Oncol 4(12):1721\u20131728","journal-title":"JAMA Oncol"},{"issue":"9","key":"6400_CR20","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.bulcan.2022.04.014","volume":"109","author":"AP Meert","year":"2022","unstructured":"Meert AP, Toffart AC, Picard M, Jaubert P, Gibelin A, Bauer P et al (2022) When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study. Bull Cancer 109(9):916\u2013924","journal-title":"Bull Cancer"},{"issue":"1","key":"6400_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13054-023-04787-x","volume":"28","author":"I Urbino","year":"2024","unstructured":"Urbino I, Lengline E, Valade S, Cerrano M, Sebert M, Raffoux E et al (2024) Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia. Crit Care 28(1):14","journal-title":"Crit Care"},{"key":"6400_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40560-019-0396-y","volume":"7","author":"L Probst","year":"2019","unstructured":"Probst L, Schalk E, Liebregts T, Zeremski V, Tzalavras A, von Bergwelt-Baildon M et al (2019) Prognostic accuracy of SOFA, qSOFA and SIRS criteria in hematological cancer patients: a retrospective multicenter study. J Intensive Care 7:41","journal-title":"J Intensive Care"},{"issue":"7","key":"6400_CR23","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H et al (1996) The SOFA (Sepsis-related organ failure Assessment) score to describe organ dysfunction\/failure. On behalf of the working group on Sepsis-Related problems of the European society of intensive care medicine. Intensive Care Med 22(7):707\u2013710","journal-title":"Intensive Care Med"},{"issue":"1","key":"6400_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven DJ, Buhlmann P (2012) MissForest\u2013non-parametric missing value imputation for mixed-type data. Bioinformatics 28(1):112\u2013118","journal-title":"Bioinformatics"},{"key":"6400_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.csda.2013.09.016","volume":"70","author":"Y Marhuenda","year":"2014","unstructured":"Marhuenda Y, Morales D, del Carmen Pardo M (2014) Information criteria for Fay\u2013Herriot model selection. Comput Stat Data Anal 70:268\u2013280","journal-title":"Comput Stat Data Anal"},{"issue":"12","key":"6400_CR26","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1093\/ndt\/gfv372","volume":"30","author":"M Darmon","year":"2015","unstructured":"Darmon M, Vincent F, Canet E, Mokart D, Pene F, Kouatchet A et al (2015) Acute kidney injury in critically ill patients with haematological malignancies: results of a multicentre cohort study from the groupe de recherche En reanimation respiratoire En Onco-Hematologie. Nephrol Dial Transpl 30(12):2006\u20132013","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"6400_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13613-023-01122-z","volume":"13","author":"AC Toffart","year":"2023","unstructured":"Toffart AC, Meert AP, Wallet F, Gibelin A, Guisset O, Gonzalez F et al (2023) ICU admission for solid cancer patients treated with immune checkpoint inhibitors. Ann Intensive Care 13(1):29","journal-title":"Ann Intensive Care"},{"issue":"1","key":"6400_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12885-020-07706-3","volume":"21","author":"H Gheerbrant","year":"2021","unstructured":"Gheerbrant H, Timsit JF, Terzi N, Ruckly S, Laramas M, Levra MG et al (2021) Factors associated with survival of patients with solid Cancer alive after intensive care unit discharge between 2005 and 2013. BMC Cancer 21(1):9","journal-title":"BMC Cancer"},{"issue":"2","key":"6400_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00277-021-04698-3","volume":"101","author":"J Garcia Borrega","year":"2022","unstructured":"Garcia Borrega J, Heger JM, Koehler P, Holtick U, Hallek M, Scheid C et al (2022) Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes-results of a retrospective analysis from a German university hospital. Ann Hematol 101(2):389\u2013395","journal-title":"Ann Hematol"},{"issue":"9","key":"6400_CR30","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00134-018-5339-x","volume":"44","author":"EE Vink","year":"2018","unstructured":"Vink EE, Azoulay E, Caplan A, Kompanje EJO, Bakker J (2018) Time-limited trial of intensive care treatment: an overview of current literature. Intensive Care Med 44(9):1369\u20131377","journal-title":"Intensive Care Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06400-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06400-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06400-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:40Z","timestamp":1749105460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06400-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6400"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06400-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki and approved by the Institutional Review of the Medical Faculty and the University Hospital Cologne on December 18, 2013 (#13\u2013380). All participating providers from the iCHOP registry obtained institutional review board approval from their institutions in accordance with local ethics regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.S. has received honoraria from Abbvie, Astro Pharma, Gilead, Jazz Pharmaceuticals, Novartis, Pfizer, and Roche; his University has received research funding from Amgen, Astellas, Astro Pharma, and Baxter; as well as competitive research grants from the Initiative Krebsforschung, the European Society of Intensive Care Medicine, and the European Commission. C.L. has received honoraria from Gilead. A.T. is an advisor for and reports receiving travel support from Kite\/Gilead. J.G.B. has received research funding and travel support from Kite\/Gilead. D.A.E. has received honoraria from Sanofi-Genzyme and Takeda. B.B. has received honoraria and research funding from Amgen, Gilead, MSD, Miltenyi, Noscendo, Novartis, Pfizer and Takeda. The remaining authors have no financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}